NEW YORK (360Dx) – Agilent Technologies announced this week that it has agreed to acquire privately-held ProZyme, a provider of glycan analysis reagents, kits, and standards. The acquisition will expand Agilent's portfolio of biopharma consumables in the glycan market, the company said. Financial terms were not disclosed. ProZyme is headquartered in Hayward, California, and employs 47 people.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.